Regen BioPharma, Inc.
RGBP
$0.00
$0.00-50.00%
OTC PK
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -0.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -0.51% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.00% | -0.51% | |||
| SG&A Expenses | -47.44% | 134.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -65.15% | 234.81% | |||
| Operating Income | 72.14% | -348.09% | |||
| Income Before Tax | 202.48% | -69.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 202.48% | -69.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 202.48% | -69.07% | |||
| EBIT | 72.14% | -348.09% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 155.67% | 43.93% | |||
| Normalized Basic EPS | 155.74% | 43.52% | |||
| EPS Diluted | 155.67% | 43.93% | |||
| Normalized Diluted EPS | 155.74% | 43.52% | |||
| Average Basic Shares Outstanding | 85.67% | 201.65% | |||
| Average Diluted Shares Outstanding | 85.67% | 201.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||